Company Research Report: Aurigene Oncology

1. Company Overview

Name:

Aurigene Oncology Limited

Mission:

Aurigene Oncology is committed to the discovery and development of novel and effective therapeutics for the treatment of cancer.

Founded:

2002 by No information is available.

Key People:

Brijesh Kumar Karnani, Chief Financial Officer

Sanjeev Giri, PhD, Senior Vice President and Head – Early Development

Subir Dubey, Vice President, Business Development

Veerendra Patil, Vice President and Head – Human Resources and Administration

Murali Ramachandra, PhD, Chief Executive Officer

Susanta Samajdar, PhD, Chief Scientific Officer

Akhil Kumar, MD, Chief Medical Officer

Headquarters:

39-40(P), KIADB Industrial Area, Phase II Electronics City Hosur Road Bangalore – 560100, Karnataka, India

Number of Employees:

425+ scientists

Revenue:

No information is available.

Known For:

Aurigene Oncology is known for its innovative therapeutics targeting various hallmarks of cancer. The company is recognized for its deep expertise in oncology-focused drug discovery and development, having discovered 21 novel chemical entities (NCEs) for clinical development and holding more than 200 NCE patents.

2. Products

Product Offerings:

Aurigene develops innovative therapeutics aimed at improving the lives of cancer patients. The company's pipeline leverages expertise in small molecule targeted protein degradation, immuno-oncology, precision oncology, and epigenetics.

Product Descriptions:

1. CA-170

Description: PD-L1/VISTA antagonist.

Key Features: Targets immune checkpoints to treat NSCLC, bladder, and kidney cancers.

2. AUR102

Description: CDK7 inhibitor.

Key Features: Targets breast and prostate cancers, and leukemia.

3. AUR103

Description: CD47 antagonist.

Key Features: Targets leukemia, lymphoma, and multiple solid tumors.

4. AUR104

Description: FABP5 inhibitor.

Key Features: Targets lymphoma and solid tumors.

5. AUR105

Description: PRMT5 inhibitor.

Key Features: Targets leukemia, lymphoma, and multiple solid tumors.

6. AUR106

Description: TIGIT antagonist.

Key Features: Multiple cancers.

7. AUR107

Description: CBP/p300 inhibitor.

Key Features: Targets NSCLC, lymphomas, leukemias, bladder cancers, and prostate cancers.

8. AUR108

Description: DHODH inhibitor.

Key Features: Targets leukemia and lymphoma.

9. AUR109

Description: DDR1/SIK2 inhibitor.

Key Features: Targets cancers of bladder, lung, breast, ovary, kidney, liver & lung fibrosis.

10. AUR101

Description: RORgt inverse agonist.

Key Features: Targets psoriasis, psoriatic arthritis, ankylosing spondylitis.

3. Recent Developments

Recent Developments:

July 5, 2022: Aurigene announced a drug discovery, development, and commercialization partnership with EQRx to combine Aurigene’s small molecule drug discovery platform and EQRx's business model to accelerate development.

June 9, 2022: Aurigene entered an exclusive collaboration and license agreement with Olema Oncology to develop novel cancer therapies.

December 14, 2021: Exelixis in-licensed a second anti-cancer compound from Aurigene following the FDA acceptance of the investigational new drug application for a Phase 1 clinical trial.

New Products Launched:

No information is available.

New Features Added to Existing Products:

No information is available.

New Partnerships:

Multi-program partnerships with EQRx, Exelixis, Olema Oncology, and Curis.

Conclusion:

Aurigene Oncology has established itself as a prominent player in the oncology-focused biotech landscape, demonstrating robust drug discovery capabilities and forming strategic partnerships aimed at accelerating the development of cancer therapeutics. With a strong emphasis on collaboration and innovation, Aurigene continues to make significant strides in the field of cancer treatment.